var data={"title":"Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6340?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information\" class=\"drug drug_general\">see &quot;Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Drug information&quot;</a> and <a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4090481\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cyanokit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12785471\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cyanokit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059323\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Cyanide</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Water Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442605\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Congenital transcobalamin deficiency:</b> IM: 1,000 <b>mcg</b> twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cobalamin C disease:</b> Limited data available: IM: 1,000 <b>mcg</b>/dose once daily was used in a single full-term neonate in conjunction with carnitine and folinic acid (Kind 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059316\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information\" class=\"drug drug_general\">see &quot;Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Due to large difference in dose for different indications; pediatric dosage may be presented in mg or <b>mcg</b>; verify dosing units.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyanide poisoning (Cyanokit): </b>Limited data available: Infants, Children, and Adolescents: <b>Note</b>: If cyanide poisoning is suspected, antidotal therapy must be given immediately: IV/Intraosseous: 70 mg/kg as a single infusion; maximum dose: 5,000 mg/dose; may repeat a second dose of 70 mg/kg (maximum dose: 5,000 mg/dose) depending on the severity of poisoning and clinical response (Mintegi 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin B<sub>12</sub> deficiency (pernicious anemia); treatment (uncomplicated disease):</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer labeling: IM: Initial: 100 <b>mcg</b>/day for &ge;2 weeks total dose range: 1,000 to 5,000 <b>mcg</b>; maintenance: 30 to 50 <b>mcg</b>/month</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: IM: Initial: 1,000 <b>mcg</b>/day for 7 days, then 100 <b>mcg</b> once weekly for 1 month; then maintenance: 100 <b>mcg</b>/month</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyanide poisoning (Cyanokit): Note:</b> If cyanide poisoning is suspected, antidotal therapy must be given immediately. IV: Initial: 5 g as single infusion; may repeat a second 5 g dose depending on the severity of poisoning and clinical response; maximum cumulative dose: 10 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vitamin B<sub>12</sub> deficiency (pernicious anemia); treatment:</b> IM: Initial: 30 <b>mcg</b> once daily for 5 to 10 days; maintenance: 100 to 200 <b>mcg</b> once per month. <b>Note:</b> Larger doses may be required in critically ill patients or if patient has neurologic disease, an infectious disease, or hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180723\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 mcg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyanokit: 5 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180710\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059327\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer 1,000 mcg/mL injection IM only; do not administer SubQ</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV/Intraosseous (Cyanokit): Administer as IV infusion over 15 minutes; if second dose is needed, administer second dose over 15 minutes to 2 hours depending upon the patient's clinical state; intraosseous may be used in pediatric patients (Mintegi 2013). Hydroxocobalamin is chemically incompatible with sodium thiosulfate and sodium nitrite and separate IV lines must be used if concomitant administration is desired <b>(the safety of coadministration is not established)</b>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180732\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for IM injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion (Cyanokit&reg;): Prior to reconstitution, store at 25&deg;C (77&deg;F): excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Temperature variation exposure allowed for transport of lyophilized form: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual transport: &le;15 days at 5&deg;C to 40&deg;C (41&deg;F to 104&deg;F) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Desert transport: &le;4 days at 5&deg;C to 60&deg;C (41&deg;F to 140&deg;F)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Freezing/defrosting cycles: &le;15 days at -20&deg;C to 40&deg;C (-4&deg;F to 104&deg;F)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Following reconstitution, store up to 6 hours at  &le;40&deg;C (104&deg;F); do not freeze. Discard any remaining solution after 6 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059326\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM injection: Treatment of pernicious anemia and other vitamin B<sub>12</sub> deficiency states; dietary supplement particularly in conditions of increased requirements (eg, pregnancy, thyrotoxicosis, hemorrhage, malignancy, liver or kidney disease) [FDA approved in pediatric patients (all ages) and adults]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion (Cyanokit): Treatment of cyanide poisoning (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180773\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IM injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (mild, transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Swelling (feeling of swelling of the entire body)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>IV infusion (Cyanokit):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest discomfort, increased blood pressure, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, memory impairment, restlessness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema (may last up to 2 weeks), pruritus, skin rash (predominantly acneiform eruption; can appear 7 to 28 days after administration and usually resolves within a few weeks), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; Metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, diarrhea, dyspepsia, dysphagia, hematochezia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine discoloration (may last up to 5 weeks after administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Lymphocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Allergic reaction (including anaphylaxis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Infusion site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Eye irritation, eye redness, swelling of eye</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dry throat, dyspnea, pharyngeal edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180728\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Hypersensitivity to hydroxocobalamin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV (Cyanokit&reg;): There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180714\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension: Cyanide poisoning: Increased blood pressure (&ge;180 mm Hg systolic or &ge;110 mm Hg diastolic) may occur with infusion; elevations usually noted at the beginning of the infusion, peak toward the end of the infusion, and return to baseline within 4 hours following the end of the infusion. May offset hypotension induced by nitrite administration or cyanide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: May cause photosensitivity; avoid direct sunlight while skin remains discolored.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: Appropriate use: Neurologic manifestations of vitamin B<sub>12</sub> deficiency will not be prevented with folic acid unless vitamin B<sub>12</sub> is also given; spinal cord degeneration might also occur when folic acid is used as a substitute for vitamin B<sub>12</sub> in anemia prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polycythemia vera: Vitamin B<sub>12</sub> deficiency masks signs of polycythemia vera; vitamin B<sub>12</sub> administration may unmask this condition. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fire victims: Fire victims may present with both cyanide and carbon monoxide poisoning. In this scenario, hydroxocobalamin is the agent of choice for cyanide intoxication since the traditional cyanide antidote that contains sodium nitrite produces methemoglobinemia and may worsen tissue hypoxia. Hydroxocobalamin can discolor the skin and exudates, complicating the assessment of burn severity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cyanokit: Use caution or consider alternatives in patients known to be allergic to, or who have experienced anaphylaxis with hydroxocobalamin or cyanocobalamin. Collection of pretreatment blood cyanide concentrations does not preclude administration and should not delay administration in the emergency management of suspected or confirmed cyanide toxicity. Only pretreatment cyanide concentrations may be useful since postinfusion concentrations may be inaccurate. Treatment of cyanide poisoning should include external decontamination and supportive therapy. Use caution with concurrent use of other cyanide antidotes; safety has not been established. Consider consultation with a poison control center at 1-800-222-1222.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Solution for IM injection: Treatment of severe vitamin B<sub>12</sub> megaloblastic anemia may result in thrombocytosis and severe hypokalemia, sometimes fatal, due to intracellular potassium shift upon anemia resolution. Use caution in folic acid deficient megaloblastic anemia; administration of vitamin B<sub>12</sub> alone is not a substitute for folic acid and might mask true diagnosis. Blunted therapeutic response to vitamin B<sub>12</sub> may occur in certain conditions (eg, infection, uremia, concurrent iron or folic acid deficiency) or in patients on medications with bone marrow suppressant properties (eg, chloramphenicol).  Approved for use as IM injection only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Hydroxocobalamin may interfere with and/or trip alarms in patients who use hemodialysis machines that rely on colorimetric technology.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299483\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180718\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13365&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May diminish the therapeutic effect of Vitamin B12.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180720\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4010117\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal studies are insufficient to determine the effect, if any, on pregnancy or fetal development. There are no adequate and well-controlled studies in pregnant women. Data on the use of hydroxocobalamin in pregnancy for the treatment of cyanide poisoning and cobalamin defects are limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059322\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin B<sub>12</sub>, hematocrit, hemoglobin, reticulocyte count, red blood cell counts, folate and iron levels should be obtained prior to treatment and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanide poisoning: Blood pressure and heart rate during and after infusion, serum lactate levels, venous-arterial PO<sub>2</sub>gradient. Pretreatment cyanide levels may be useful as post infusion levels may be inaccurate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Megaloblastic anemia: In addition to normal hematological parameters, serum potassium and platelet counts should be monitored during therapy, particularly in the first 48 hours of treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059325\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin B<sub>12</sub>: Normal: 200 to 900 pg/mL; vitamin B<sub>12</sub> deficiency: &lt;200 pg/mL; megaloblastic anemia: &lt;100 pg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanide poisoning: Blood cyanide levels may be used for diagnosis confirmation; however, reliable levels require prompt testing and proper storage conditions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanide levels related to clinical symptomatology:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tachycardia/flushing: 0.5 to mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Obtundation: 1 to 2.5 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coma: 2.5 to 3 mg/L</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Death: &gt;3 mg/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F180713\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Hydroxocobalamin (vitamin B<sub>12a</sub>) is a precursor to cyanocobalamin (vitamin B<sub>12</sub>). Cyanocobalamin acts as a coenzyme for various metabolic functions, including fat and carbohydrate metabolism and protein synthesis, used in cell replication and hematopoiesis. In the presence of cyanide, each hydroxocobalamin molecule can bind one cyanide ion by displacing it for the hydroxo ligand linked to the trivalent cobalt ion, forming cyanocobalamin, which is then excreted in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4010127\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Following IV administration of Cyanokit&reg;:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Significant; forms various cobalamin-(III) complexes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 26-31 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (50% to 60% within initial 72 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059332\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Cyanocobalamin is preferred over hydroxocobalamin as a treatment agent for anemia due to reports of antibody formation to the hydroxocobalamin-transcobalamin complex. Cyanide is a clear colorless gas or liquid with a faint bitter almond odor. Cyanide reacts with trivalent ions in cytochrome oxidase in the mitochondria leading to histotoxic hypoxia and lactic acidosis. Signs and symptoms of cyanide toxicity include headache, altered mental status, dyspnea, mydriasis, chest tightness, nausea, vomiting, tachycardia/hypertension (initially), bradycardia/hypotension (later), seizures, cardiovascular collapse, or coma. Guidelines suggest that at least 10 <b>g</b> be stocked. This is enough to treat one patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2009). If several victims, consider initiating with half-dose of hydroxocobalamin up to 5,000 mg/dose (Mintegi 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323186\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Hydroxocobalamin Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg/mL (30 mL): $38.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cyanokit Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 g (1): $985.58</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539877\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aquo-Cytobion (DE);</li>\n      <li>Articlox (GR);</li>\n      <li>B12 Depot-Rotexmedica (DE);</li>\n      <li>B12-Depot-Hevert (DE);</li>\n      <li>B12-Depot-Vicotrat (DE);</li>\n      <li>Behepan (SE);</li>\n      <li>Benzoral (AR);</li>\n      <li>Berubi-long (DE);</li>\n      <li>Bradirubra (IT);</li>\n      <li>Cobalin-H (AE, GB, MT, QA);</li>\n      <li>Cobalparen (DE);</li>\n      <li>Cobalvit (IT);</li>\n      <li>Cohemin Depot (FI);</li>\n      <li>Cyano Kit (JP);</li>\n      <li>Cyanokit (ES, FR, HR, MT, PL);</li>\n      <li>Cynomin H (BD);</li>\n      <li>Depovit-B 12 (EG);</li>\n      <li>Depovit-B12 (AE, QA);</li>\n      <li>Dodecavit (FR);</li>\n      <li>Doleven (JP);</li>\n      <li>Dosixbe (AR);</li>\n      <li>Douzabin Retard Forte (LB);</li>\n      <li>Forta B 5.000 (BE);</li>\n      <li>Forta B12 (BE, LU);</li>\n      <li>Hepavit (AT);</li>\n      <li>Hycomin (KR);</li>\n      <li>Hydrocobamine (NL);</li>\n      <li>Hydroxo 5.000 (FR, LU);</li>\n      <li>Hydroxo-B 12 (AU);</li>\n      <li>Idroxocobalamina (IT);</li>\n      <li>Lanobin (KR);</li>\n      <li>Lisoneurin (AR);</li>\n      <li>Lophakomp-B 12 Depot (DE);</li>\n      <li>Megamilbedoce (ES);</li>\n      <li>Minedrox (PE);</li>\n      <li>Neo-B12 (AU);</li>\n      <li>Neo-Cytamen (GB, IE, IT, NZ);</li>\n      <li>Novidroxin (DE);</li>\n      <li>Novobedouze (BE, LU);</li>\n      <li>OH B12 (IT);</li>\n      <li>OHB12 (PT);</li>\n      <li>Rasedon 500 (JP);</li>\n      <li>Rubranova (BR);</li>\n      <li>Tarupain (KR);</li>\n      <li>Twelvmin-s (JP);</li>\n      <li>Vibeden (DK);</li>\n      <li>Vitamin B12 Depot (NO);</li>\n      <li>Vitamin B12-Depot-Injektopas (DE);</li>\n      <li>Vitarubin-Depot (CH);</li>\n      <li>Westhidroxo (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Borron SW, Caravati EM, et al, &quot;Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care,&quot; <i>Ann Emerg Med</i>, 2009, 54(3):386-394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/19406507/pubmed\" target=\"_blank\" id=\"19406507\">19406507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geraci MJ, McCoy SL, and Aquino ME, &quot;Woman With Red Uurine: Hydroxocobalamin-Induced Chromaturia,&quot; <i>J Emerg Med</i>, 2012, 43(3):e207-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/21530137/pubmed\" target=\"_blank\" id=\"21530137\">21530137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kind T, Levy J, Lee M, et al, &quot;Cobalamin C Disease Presenting as Hemolytic-Uremic Syndrome in the Neonatal Period,&quot; <i>J Pediatr Hematol Oncol</i>, 2002, 24(4):327-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/11972107/pubmed\" target=\"_blank\" id=\"11972107\">11972107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mintegi S, Clerigue N, Tipo V, et al. Pediatric cyanide poisoning by fire smoke inhalation: a European expert consensus. Toxicology Surveillance System of the Intoxications Working Group of the Spanish Society of Paediatric Emergencies. <i>Pediatr Emerg Care</i>. 2013;29(11):1234-1240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/24196100/pubmed\" target=\"_blank\" id=\"24196100\">24196100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shepherd G and Velez LI, &quot;Role of Hydroxocobalamin in Acute Cyanide Poisoning,&quot; <i>Ann Pharmacother</i>, 2008, 42(5):661-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-pediatric-drug-information/abstract-text/18397973/pubmed\" target=\"_blank\" id=\"18397973\">18397973</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13365 Version 92.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F4090481\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12785471\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059323\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442605\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059316\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F180723\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F180710\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059327\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F180732\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059326\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F180773\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F180728\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F180714\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299483\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F180718\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F180720\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4010117\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059322\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1059325\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F180713\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F4010127\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1059332\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323186\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539877\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13365|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-drug-information\" class=\"drug drug_general\">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Drug information</a></li><li><a href=\"topic.htm?path=hydroxocobalamin-vitamin-b12a-supplement-and-cyanide-antidote-patient-drug-information\" class=\"drug drug_patient\">Hydroxocobalamin (vitamin B12a supplement and cyanide antidote): Patient drug information</a></li></ul></div></div>","javascript":null}